- Home
- EVMN vs RLMD Comparison
EVMN vs RLMD Comparison
Compare EVMN & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVMN | RLMD |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 405.2M | 461.9M |
| IPO Year | 2025 | 2012 |
Fundamental Metrics
Financial Performance| Metric | EVMN | RLMD |
|---|---|---|
| Price | $12.48 | $4.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $43.88 | $12.40 |
| AVG Volume (30 Days) | 445.8K | ★ 1.0M |
| Earning Date | 06-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.23 | 45.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,000,000.00 | $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 85.71 | ★ 154.83 |
| 52 Week Low | $10.47 | $1.13 |
| 52 Week High | $33.20 | $8.00 |
Technical Indicators
Market Signals| Indicator | EVMN | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 40.78 | 36.49 |
| Support Level | $12.07 | $4.29 |
| Resistance Level | $15.06 | $4.55 |
| Average True Range (ATR) | 0.70 | 0.18 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 4.36 | 30.94 |
Price Performance
Historical ComparisonAbout EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.